CDEK
← All drugs Report issue

il-7

Recombinant proteinexperimental

Interleukin 7 (IL-7) is a protein that in humans is encoded by the IL7 gene. — Wikipedia

Clinical trial activity

29 trials · 30 clinical orgs · 0 marketing orgs

Phase 1
16
Phase 2
17
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2003 (NCT00062049)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • il-7
  • il-7
  • interleukin-7
  • interleukin-7
  • recombinant human interleukin-7

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06523699Phase 1Oct 31, 2024Accentia Biopharmaceuticals, Washington University in St. Louis
NCT05600920Phase 1/Phase 2 (Phase 2)Dec 29, 2022National Institute of Allergy and Infectious Diseases (NIAID)
NCT04927169Phase 2Mar 1, 2021Accentia Biopharmaceuticals, Federal University of Sao Paulo, ReSolution Latin America S.A.
NCT04501796Phase 1Aug 31, 2020NeoImmuneTech, Inc.
NCT04407689Phase 2Jun 1, 2020Accentia Biopharmaceuticals, Amarex Clinical Research, University of Limoges
NCT04379076Phase 2May 14, 2020Accentia Biopharmaceuticals, Amarex Clinical Research, University of London
NCT04154826Phase 2Jan 6, 2020Accentia Biopharmaceuticals, Washington University in St. Louis
NCT04054752Phase 1Aug 16, 2019National Cancer Institute (NCI), NeoImmuneTech, Inc.
NCT03941769Phase 1Jul 31, 2019National Cancer Institute (NCI), University of Texas at Houston
NCT03929107Phase 2Mar 28, 2019Zhejiang University
NCT03513952Phase 2Sep 30, 2018Cancer Immunotherapy Trials Network, National Cancer Institute (NCI)
NCT02640807Phase 2Jan 1, 2016Accentia Biopharmaceuticals, Vanderbilt University, Washington University in St. Louis
NCT02797431Phase 2Jan 1, 2016Accentia Biopharmaceuticals, University of Limoges, Vanderbilt University
NCT02659800N/ANov 1, 2015Accentia Biopharmaceuticals, Johns Hopkins University, National Cancer Institute (NCI)
NCT01881867Phase 2Mar 1, 2015Cancer Immunotherapy Trials Network, National Cancer Institute (NCI), University of Washington
NCT01368107Phase 2Jun 1, 2011Centre Leon Berard, Cytheris, Government of France
NCT01019551Phase 2Sep 1, 2010Cytheris, Merck, Objectif Recherche Vaccins SIDA, Pfizer, University of California, San Francisco
NCT01190111Phase 2Jan 1, 2010Case Western Reserve University, Cytheris
NCT01024894Phase 1/Phase 2 (Phase 2)Jan 1, 2009Cytheris, Kaohsiung Medical University
NCT01025297Phase 1/Phase 2 (Phase 2)Jul 1, 2008Cantonal Hospital of St. Gallen, Cytheris
Showing 20 of 29 trials
Page 1 / 2

Organizations

Research & Development (30)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CytherisFor profit9722007
Accentia BiopharmaceuticalsFor profit8532015
National Cancer Institute (NCI)Government8432003
National Institutes of Health (NIH)Government5122003
National Institute of Allergy and Infectious Diseases (NIAID)Government4322005
Case Western Reserve UniversityAcademic/Hospital3022005
Washington University in St. LouisAcademic/Hospital3122016
Amarex Clinical ResearchFor profit2012020
Cancer Immunotherapy Trials NetworkAcademic/Hospital2012015
NeoImmuneTech, Inc.For profit2112019
University of LimogesAcademic/Hospital2112016
Vanderbilt UniversityAcademic/Hospital2012016
Cantonal Hospital of St. GallenAcademic/Hospital1012008
Centre Leon BerardAcademic/Hospital1112011
CHU Henri MondorAcademic/Hospital1012007
Cornell UniversityAcademic/Hospital1012008
Federal University of Sao PauloAcademic/Hospital1012021
Government of FranceGovernment1012011
Johns Hopkins UniversityAcademic/Hospital1112015
Kaohsiung Medical UniversityAcademic/Hospital1012009
30 organizations
Page 1 / 2